A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data11Financial disclosure: This study was sponsored by Novartis Ophthalmics, Inc., the distributor of unoprostone isopropyl (Rescula®) in Europe and the U.S. Dr. Nordmann is a consultant for Novartis Ophthalmics, Inc. The investigators received compensation for conducting the study, but have no proprietary or stock interest in Novartis Ophthalmics, Inc.

2002 ◽  
Vol 133 (1) ◽  
pp. 1-10 ◽  
Author(s):  
Jean-Philippe Nordmann ◽  
Beat Mertz ◽  
Natalia C Yannoulis ◽  
Christine Schwenninger ◽  
Barry Kapik ◽  
...  
Keyword(s):  
Ocular Hypertension ◽  
Primary Open Angle Glaucoma ◽  
Open Angle Glaucoma ◽  
Open Angle ◽  
Efficacy And Safety ◽  
Pseudoexfoliation Glaucoma ◽  
The U.S

scholarly journals Efficacy and safety of latanoprost versus pilocarpine/timolol maleate fixed combination in patients with primary open-angle glaucoma or ocular hypertension

2008 ◽  
Vol 86 (8) ◽  
pp. 860-865 ◽  
Author(s):  
Józef Kałużny ◽  
Roman Sobecki ◽  
Krystyna Czechowicz-Janicka ◽  
Dariusz Kecik ◽  
Bartłomiej J. Kałużny ◽  
...  
Keyword(s):  
Ocular Hypertension ◽  
Primary Open Angle Glaucoma ◽  
Fixed Combination ◽  
Open Angle Glaucoma ◽  
Open Angle ◽  
Efficacy And Safety ◽  
Timolol Maleate

Comparison of Two Fixed Beta-Blocker-Pilocarpine Combinations

1997 ◽  
Vol 7 (4) ◽  
pp. 351-356 ◽  
Author(s):  
◽  
A. M. Bron ◽  
C. P. Garcher ◽  
D. Sirbat ◽  
C. M. Allaire ◽  
...  
Keyword(s):  
Ocular Hypertension ◽  
Beta Blocker ◽  
Statistical Difference ◽  
Primary Open Angle Glaucoma ◽  
Fixed Combination ◽  
Open Angle Glaucoma ◽  
Ophthalmic Solution ◽  
Open Angle ◽  
Efficacy And Safety ◽  
Group A

Purpose To compare the efficacy and safety of a newly developed ophthalmic solution containing carteolol 2% and pilocarpine (2% (CBS341A) with a timolol 0.5% and pilocarpine 2% fixed combination. Patients and Methods. A randomized, double-masked, multicenter study was conducted in 209 patients with primary open-angle glaucoma or ocular hypertension, whose intraocular pressure (IOP) was higher than 21 mm Hg on bet-blocker twice a day alone. The test medications were administered twice daily for 4 months. IOP was measured at 9 and 11 a.m. at the beginning of the study (with beta-blocker alone) and after one and four months of treatment. Adverse effects were recorded. Results Both combinations caused a similar, statistically significant decrease in IOP. At four months, in the CBS341A group a 2.4 mm Hg (9%) reduction in IOP was achieved at 9 a.m. and 4.1 mm Hg (17.3%) at 11 a.m. compared with respectively 3 mm Hg (11%) and 4.5 mm Hg (19.5%) in the timolol-pilocarpine group. No statistical difference was observed between the two groups in safety and efficacy. Conclusions The carteolol-pilocarpine combination appears as safe and as effective as the timolol-pilocarpine combination in the medical treatment of primary open-angle glaucoma or ocular hypertension.

scholarly journals Efficacy and safety of SNJ-1656 in primary open-angle glaucoma or ocular hypertension

2015 ◽  
Vol 93 (5) ◽  
pp. e393-e395 ◽  
Author(s):  
Toshihiro Inoue ◽  
Hidenobu Tanihara ◽  
Hideki Tokushige ◽  
Makoto Araie
Keyword(s):  
Ocular Hypertension ◽  
Primary Open Angle Glaucoma ◽  
Open Angle Glaucoma ◽  
Open Angle ◽  
Efficacy And Safety
Sign in / Sign up

Export Citation Format

Share Document